Lyme disease

1. High-Yield Summary

Lyme disease is a multi-system vector-borne spirochetal infection caused by Borrelia burgdorferi (sensu stricto in North America; Borrelia afzelii and Borrelia garinii in Eurasia) and transmitted through the bite of infected Ixodes ticks. Lyme arthritis represents the hallmark musculoskeletal manifestation of late disseminated (Stage 3) infection, requiring clear diagnostic and therapeutic algorithms for orthopaedic surgeons:

• Articular Predilection & Clinical Presentation: Late Lyme arthritis classically manifests months to years after initial inoculation as an intermittent or persistent monoarthritis or asymmetric oligoarthritis. The knee is affected in over 80% to 85% of cases, followed by the shoulder, ankle, elbow, and hip. The classic physical examination reveals a massive, tense, painless or mildly tender joint effusion with preserved passive range of motion, disproportionately mild erythema, and absence of systemic toxicity.
• Diagnostic Benchmarks: Serum serologic testing follows a validated two-tiered paradigm: sensitive enzyme immunoassay (EIA) screening followed by Western blot immunoblotting (Standard Two-Tiered Testing, STTT) or sequential dual enzyme immunoassays (Modified Two-Tiered Testing, MTTT). In late Lyme arthritis, IgG serology is positive in virtually 100% of patients (requiring at least 5 of 10 diagnostic IgG Western blot bands). Arthrocentesis demonstrates inflammatory synovial fluid with a mean leukocyte count of 20,000 to 60,000 cells/mcL with polymorphonuclear neutrophil (PMN) predominance, negative routine bacterial Gram stain and cultures, and positive synovial fluid B. burgdorferi real-time polymerase chain reaction (PCR).
• Pediatric Differentiation from Septic Arthritis: In endemic regions, pediatric patients presenting with acute knee effusions are differentiated from pyogenic septic arthritis and transient synovitis using validated clinical prediction models (e.g., Baldwin criteria). While septic arthritis produces severe guarding, inability to bear weight, high fever, and elevated C-reactive protein (CRP ≥4.0 to 5.0 mg/dL), children with Lyme arthritis frequently maintain ambulation and exhibit CRP levels <4.0 mg/dL.
• Medical Management Algorithm: First-line medical therapy consists of oral Doxycycline (100 mg PO BID for 28 days for adults and children of all ages per updated guidelines) or Amoxicillin (500 mg PO TID for 28 days for pregnant patients or children when preferred). Persistent or recurrent joint swelling after 1 month warrants either a second 28-day oral antibiotic course or intravenous Ceftriaxone (2 g IV daily for 14 to 28 days), achieving disease eradication in over 85% to 90% of cases.
• Antibiotic-Refractory Synovitis & Operative Intervention: Approximately 5% to 10% of patients develop antibiotic-refractory (post-infectious) Lyme arthritis characterized by persistent proliferative synovitis despite pathogen clearance, driven by autoimmune cross-reactivity in patients harboring HLA-DRB1 susceptibility alleles. Management escalates through NSAIDs, intra-articular corticosteroids, and disease-modifying antirheumatic drugs (DMARDs, e.g., methotrexate, TNF-alpha inhibitors). Arthroscopic subtotal synovectomy via anterior, accessory suprapatellar, and trans-notch posterior portals is indicated for debilitating proliferative synovitis refractory to medical therapy persisting beyond 6 to 12 months.

2. Anatomy and Pathophysiology

Synovial Microvascularization and Target Joint Predilection

The native joint capsule is lined by a metabolically active synovial membrane composed of a superficial intimal layer (1 to 3 cells deep of type A macrophage-like and type B fibroblast-like synoviocytes) and a deeper, highly vascularized subintimal stroma. Unlike true mucosal or cutaneous boundaries, synovial tissue lacks an epithelial basement membrane and continuous tight junctions. This discontinuous architecture permits rapid transudation of plasma proteins and provides unrestricted access for blood-borne pathogens during transient spirochetemia.

Borrelia burgdorferi exhibits pronounced tropism for fibrous connective tissues and synovial microvasculature. The spirochete utilizes surface adhesins to bind extracellular matrix components, specifically fibronectin, decorin, and glycosaminoglycans concentrated within large synovial joints. The knee joint is the primary clinical target, accounting for greater than 80% of all Lyme arthritis episodes. Secondary joint targets include the shoulder (glenohumeral joint and subacromial bursa), ankle (talocrural joint), elbow, and hip. Axial joints and the small articulations of the hands and feet are characteristically spared.

Surgical Approaches and Internervous Planes for Knee Arthrotomy

When diagnostic ambiguity or extensive tissue debridement necessitates open joint exposure, knowledge of surgical intervals and neurovascular anatomy is paramount:

• Medial Parapatellar Arthrotomy: The classic open exposure traverses the rectus femoris tendon, medial patellar retinaculum, and joint capsule. This approach does not exploit a true internervous plane, as the quadriceps mechanism and medial retinaculum are supplied by the femoral nerve. The primary nerve branch at risk is the infrapatellar branch of the saphenous nerve (IPBSN), which crosses the anterior joint line obliquely.
• Lateral Parapatellar Arthrotomy: Utilized for isolated lateral compartment pathology or lateral release. The interval lies between the vastus lateralis (femoral nerve) and the lateral border of the rectus femoris and patellar tendon. The superior lateral genicular artery crosses the superior aspect of this exposure and requires surgical cauterization.

Arthroscopic Portals and Neurovascular Danger Zones

Surgical synovectomy for antibiotic-refractory Lyme arthritis is performed arthroscopically. Comprehensive synovectomy requires systematic access to anterior, suprapatellar, gutter, and posterior compartments. Each portal carries specific neurovascular hazards:

• Anterolateral (AL) Portal: Established 1 cm above the lateral joint line and 1 cm lateral to the patellar tendon. Provides universal diagnostic visualization. Overly inferior placement risks iatrogenic transection of the anterior horn of the lateral meniscus.
• Anteromedial (AM) Portal: Established 1 cm above the medial joint line and 1 cm medial to the patellar tendon under direct needle localization. The infrapatellar branch of the saphenous nerve (IPBSN) courses along this subcutaneous boundary; horizontal skin incisions parallel to skin tension lines minimize iatrogenic neuroma formation compared to vertical incisions.
• Superomedial and Superolateral Portals: Placed 2 to 3 cm superior to the proximal pole of the patella on either side of the quadriceps tendon. Essential for high-flow inflow/outflow cannulation and motorized debridement of dense villous synovitis within the suprapatellar pouch.
• Posteromedial (PM) Portal: Placed in the posteromedial soft spot, bounded by the posterior border of the medial femoral condyle, medial collateral ligament, and semimembranosus/pes anserinus tendons. Visualized through the intercondylar notch with a 30-degree or 70-degree arthroscope. Danger zone: The saphenous nerve and great saphenous vein run superficial to the capsule immediately posterior to this portal. To maximize the safety margin, the knee must be held in 90 degrees of flexion to allow the popliteal neurovascular bundle to displace posteriorly, and the joint must be fully distended prior to trochar insertion.
• Posterolateral (PL) Portal: Established superior to the fibular head, posterior to the iliotibial band, and anterior to the biceps femoris tendon. Danger zone: The common peroneal nerve courses posteroinferior to the biceps femoris tendon and wraps around the fibular neck. Establishing the portal anterior to the biceps tendon with the knee at 90 degrees of flexion protects the nerve.
• Central Popliteal Neurovascular Bundle: The popliteal artery, popliteal vein, and tibial nerve lie immediately posterior to the central posterior capsule and posterior cruciate ligament (PCL). During trans-notch debridement and posterior synovectomy, motorized shavers and radiofrequency ablators must face anteriorly toward the joint space, strictly avoiding penetration through the posterior capsule.

3. Pathogenesis

Vector Dynamics and Spirochetal Transmission

Borrelia burgdorferi is an obligate parasitic, microaerophilic, motile spirochete measuring 10 to 30 micrometers in length and 0.2 to 0.5 micrometers in width. Motility is driven by periplasmic flagella (axial filaments) residing within the periplasmic space between the peptidoglycan cell wall and outer membrane, imparting a distinctive corkscrew locomotion that enables efficient penetration through dense extracellular matrix and viscous host fluids.

Transmission occurs primarily through the bite of nymphal or adult female hard-bodied ticks of the genus Ixodes. In the northeastern, mid-Atlantic, and north-central United States, Ixodes scapularis (the blacklegged or deer tick) serves as the primary vector, whereas Ixodes pacificus mediates transmission along the Pacific Coast. In Europe and Asia, Ixodes ricinus and Ixodes persulcatus are the predominant vectors. Spirochete transmission is time-dependent: spirochetes reside in a quiescent state within the tick midgut. Ingestion of a blood meal triggers bacterial replication and active migration to the tick salivary glands. Consequently, tick attachment for at least 36 to 48 hours is typically required for successful transmission; tick detachment within 24 hours results in an exceptionally low transmission probability.

Phenotypic Switching: Outer Surface Proteins (Osps)

During the transmission cycle, B. burgdorferi undergoes marked phenotypic remodeling of its outer membrane lipoproteins in response to mammalian host cues (increased temperature and reduced pH):

• Outer Surface Protein A (OspA) and OspB: In the unfed tick gut, spirochetes predominantly express OspA, which binds specifically to the tick gut receptor TROSPA (tick receptor for OspA), tethering the organism to the gut wall. Upon ingestion of warm mammalian blood, OspA expression is rapidly down-regulated.
• Outer Surface Protein C (OspC): Concomitant with OspA suppression, the spirochete up-regulates OspC, an essential surface lipoprotein that facilitates detachment from the midgut, migration to the tick salivary glands, invasion of host skin, and resistance against early mammalian innate immune clearance.
• VlsE and Antigenic Variation: Once established in the host, B. burgdorferi continually varies the surface-exposed variable lipoprotein VlsE through non-reciprocal segmental gene conversion, enabling immune evasion and persistent chronic infection.

Endothelial Attachment, Tissue Tropism, and Dissemination

Following local intradermal replication (which produces the expanding annular erythema migrans lesion), spirochetes penetrate cutaneous microvessels and regional lymphatics. Vascular dissemination is mediated by specific bacterial adhesins. Decorin-binding proteins A and B (DbpA and DbpB) bind host decorin (a small leucine-rich proteoglycan abundant in connective tissue and joint capsule). The fibronectin-binding protein BBK32 mediates tethering to vascular endothelial surfaces under physiologic shear stress. Spirochetes actively extravasate across synovial microvascular endothelial walls, anchoring directly into the synovial subintima.

Synovial Immunopathogenesis, TLR2 Activation, and Autoimmune Mimicry

Within the joint cavity, B. burgdorferi triggers a robust biphasic inflammatory cascade:

• Innate Pattern Recognition: Outer surface lipoproteins act as potent pathogen-associated molecular patterns (PAMPs), activating Toll-like receptor 2 (TLR2) in conjunction with TLR1 on macrophages, dendritic cells, and synovial fibroblasts. TLR2 signaling initiates nuclear translocation of NF-kappa-B, stimulating massive transcription of pro-inflammatory cytokines (IL-1beta, TNF-alpha, IL-6), chemokines (CXCL8/IL-8, CXCL9, CXCL10), and destructive matrix metalloproteinases (MMP-1, MMP-3, MMP-13).
• Neutrophilic Influx: High local concentrations of CXCL8 drive rapid recruitment of polymorphonuclear neutrophils into the synovial fluid, accounting for the acute inflammatory cell counts observed during arthrocentesis.
• Adaptive Th1/Th17 Response: Infiltration of the synovial stroma by CD4+ helper T cells (predominantly interferon-gamma-producing Th1 cells and IL-17-producing Th17 cells) and B lymphocytes leads to marked synovial lining hyperplasia, lymphoid follicle formation, and villous hypertrophy resembling rheumatoid pannus.
• Pathogenesis of Refractory Lyme Arthritis: In approximately 5% to 10% of patients, proliferative synovitis persists for months to years despite comprehensive eradication of live spirochetes by antibiotics. This antibiotic-refractory state is strongly associated with human leukocyte antigen (HLA) class II alleles, specifically HLA-DRB1*0401, HLA-DRB1*0101, and HLA-DRB1*0404. In these individuals, molecular mimicry between an immunodominant OspA epitope (OspA165-173) and human endothelial cell autoantigens (such as annexin A2 and endothelial cell growth factor [ECGF]) maintains a self-sustaining autoimmune loop in the complete absence of viable organisms.

4. Natural History

Epidemiologic Patterns and Transmission Seasonality

Lyme disease represents the most common vector-borne infection in North America and Europe. In the United States, the Centers for Disease Control and Prevention (CDC) estimates that approximately 476,000 cases are diagnosed annually based on insurance claims data, with over 95% of cases concentrated within 15 high-incidence states in the Northeast, Mid-Atlantic, and Upper Midwest regions. A secondary endemic pocket exists in northern California and Oregon mediated by I. pacificus.

The transmission curve demonstrates marked seasonality. The majority of human transmissions occur between May and August, coinciding with the peak questing activity of Ixodes nymphs. Nymphs are tiny (approximately 1 to 2 mm in size, comparable to a poppy seed), making them difficult to detect and allowing sufficient feeding time for spirochetal transmission. The age distribution is characteristically bimodal, with a primary peak in children aged 5 to 14 years and a secondary peak in adults aged 50 to 65 years. A slight male predominance (55% to 60%) is observed, likely reflecting occupational and recreational outdoor exposure profiles.

Stage 1: Early Localized Infection (Days 1 to 30)

Early localized infection begins at the cutaneous inoculation site within 3 to 30 days (average 7 to 10 days) following the tick bite:

• Erythema Migrans (EM): Occurs in approximately 70% to 80% of infected individuals. It begins as a solitary erythematous macule or papule that expands centrifugally over days to weeks, reaching a diameter of at least 5 cm (and frequently exceeding 15 to 20 cm). Central clearing produces the classic target or “bull’s-eye” appearance in approximately 30% to 40% of cases, though solid homogeneous erythema is equally common.
• Constitutional Manifestations: Accompanied by low-grade fever, malaise, fatigue, headache, neck stiffness, and generalized migratory arthralgias and myalgias. True articular effusion is distinctly absent during Stage 1.

Stage 2: Early Disseminated Infection (Weeks to Months)

Untreated spirochetes disseminate through the bloodstream and lymphatic network to multiple organ systems:

• Cutaneous Signs: Multiple secondary annular erythema migrans lesions develop across the trunk and extremities, characteristically smaller than the primary lesion.
• Neurologic (Early Neuroborreliosis, 10% to 15%): Manifests as the classic triad of lymphocytic meningitis, cranial neuritis (unilateral or bilateral facial nerve palsy / Bell palsy in over 80% of neuroborreliosis cases), and motor/sensory radiculoneuropathy (Bannwarth syndrome).
• Cardiac (Lyme Carditis, 1% to 4%): Characterized by acute-onset, fluctuating atrioventricular (AV) nodal conduction block (ranging from first-degree to complete third-degree heart block), acute myopericarditis, and mild left ventricular dysfunction.
• Musculoskeletal Signs: Migratory, fleeting musculoskeletal pain involving joints, tendons, bursae, and muscles without persistent objective swelling.

Stage 3: Late Disseminated Lyme Disease and Chronic Synovitis (Months to Years)

Late disseminated disease develops in approximately 60% of untreated patients, emerging months to over a year after the initial bite:

• Lyme Arthritis: The signature clinical manifestation of Stage 3 disease. Manifests as recurrent or persistent attacks of marked joint swelling and effusion, most commonly monoarticular or asymmetric oligoarticular. The knee is involved in over 80% of patients. Left untreated, untreated attacks typically last weeks to months before spontaneously remitting, only to recur with progressive joint damage.
• Chronic Proliferative Synovitis: A subset of patients progresses from intermittent episodic effusion to continuous, relentless synovitis characterized by extensive villonodular synovial hypertrophy, Baker cyst formation, popliteal cyst dissection, and slowly progressive articular cartilage erosion.
• Late Neuroborreliosis: A rare manifestation in North America, presenting as chronic axonal polyneuropathy, subacute encephalopathy, or leukoencephalitis.

5. Clinical Presentation

History

Eliciting a targeted clinical history is essential for establishing pre-test probability and avoiding misdiagnosis:

• Geographic Exposure: Document residence in, or travel to, designated Lyme-endemic corridors (Northeast US from Maine to Virginia, Upper Midwest, Northern California, or Central/Northern Europe). Exposure during spring or summer months significantly elevates suspicion.
• Tick Bite Recall: A definitive history of an attached tick bite is recalled by only 20% to 30% of patients with confirmed Lyme arthritis. Absence of a known tick bite should never exclude the diagnosis.
• Antecedent Clinical Markers: Inquire specifically regarding a prior expanding circular rash (erythema migrans), summer flu-like illness, facial drooping or Bell palsy, or unexplained palpitations/syncope occurring 2 to 12 months prior to joint symptoms.
• Symptom Quality & Pain Discordance: Patients typically report insidious, progressive joint swelling, stiffness, and a mechanical sensation of fullness. The hallmark of Lyme arthritis is the striking discordance between the massive size of the joint effusion and the modest level of pain. Patients frequently continue to bear weight and participate in activities, in sharp contrast to the agonizing, incapacitating pain of acute bacterial septic arthritis.

Physical Examination

The physical examination should systematically assess joint effusion volume, active/passive range of motion, neurovascular status, and provocative maneuvers:

• Inspection and Palpation: Prominent, tense distension of the suprapatellar pouch and parapatellar gutters. The joint is typically “cold” or exhibits only mild warmth; intense erythema, calor, and shiny overlying skin are uncommon and should heighten suspicion for acute pyogenic infection.
• Range of Motion: Passive range of motion is remarkably preserved. Mild pain is elicited only at terminal flexion (due to capsular distension) or terminal extension. Complete resistance to gentle passive range of motion is characteristic of pyogenic septic arthritis, not uncomplicated Lyme arthritis.
• Patellar Ballottement Test: The knee is positioned in full extension, the suprapatellar pouch is compressed downward with one hand, and the patella is tapped firmly against the femoral trochlea. A distinct tap or floating bounce confirms a large intra-articular fluid effusion [Sensitivity 89%, Specificity 83%].
• Fluid Wave / Bulge Sign: In smaller effusions, fluid is evacuated from the medial compartment by stroking upward, followed by a downward sweep along the lateral suprapatellar pouch. A visible fluid wave bulging into the medial sulcus confirms effusion [Sensitivity 75%, Specificity 90%].
• Weight-Bearing Tolerance Maneuver: The patient is requested to stand, ambulate, and bear full weight on the affected limb. Over 70% to 80% of children and adults with acute Lyme knee arthritis can bear weight (often with an antalgic gait), whereas fewer than 15% of patients with acute pyogenic bacterial septic arthritis tolerate weight-bearing [Sensitivity 82%, Specificity 85% for distinguishing Lyme from septic arthritis].
• Popliteal Fossa Examination: Palpation of the posteromedial popliteal space to identify secondary Baker cysts. Ruptured popliteal cysts present with acute posterior calf swelling, ecchymosis, and pain mimicking acute deep vein thrombosis (pseudothrombophlebitis).

6. Imaging and Diagnostic Studies

Plain Radiography and Advanced Magnetic Resonance Imaging

Diagnostic imaging serves primarily to evaluate the extent of soft tissue involvement and rule out alternative diagnoses such as acute osteomyelitis, osteochondritis dissecans, or bone tumors:

• Plain Radiographs: Standard standing AP, lateral, and Merchant/sunrise views of the knee (or AP pelvis and frog-leg lateral for hip presentations). Findings in early or uncomplicated Lyme arthritis are limited to soft tissue distension, displacement of the pre-femoral and suprapatellar fat pads, and widening of the anterior joint space (>5 to 10 mm on cross-table lateral). True cortical destruction, subchondral bone loss, and periosteal reaction are absent; their presence suggests pyogenic osteomyelitis or aggressive septic arthritis. In chronic refractory cases, mild diffuse osteopenia, marginal erosions, and joint space narrowing may appear.
• Magnetic Resonance Imaging (MRI): MRI is not required for routine initial diagnosis but is highly informative when evaluating diagnostic ambiguity or refractory disease. Characteristic findings include massive joint effusion with prominent, diffuse synovial thickening, frond-like villous hypertrophy (pannus), and intense, homogeneous synovial enhancement following intravenous gadolinium administration. Large popliteal cysts are frequently identified. Subchondral bone marrow edema is typically mild or absent, which distinguishes Lyme arthritis from pyogenic septic arthritis and tuberculous arthritis where prominent subchondral marrow edema and subchondral erosions predominate.

Arthrocentesis and Synovial Fluid Cytology

Arthrocentesis is mandatory in any acute monoarticular effusion to rule out pyogenic bacterial infection and crystal-induced arthropathy:

• Gross Appearance: Turbid, yellow, non-viscous inflammatory transudate.
• Synovial White Blood Cell (WBC) Count: Typically ranges from 20,000 to 60,000 cells/mcL (mean ~35,000 to 45,000 cells/mcL). However, a significant clinical pitfall is that synovial WBC counts can range up to 100,000 cells/mcL or higher, directly overlapping values classically associated with acute pyogenic bacterial septic arthritis.
• Synovial Differential: Predominantly neutrophilic, with polymorphonuclear leukocytes (PMNs) comprising 50% to 80% of the total leukocyte count.
• Microbiological Assays: Synovial fluid Gram stain and routine aerobic/anaerobic bacterial cultures are uniformly negative. Routine culturing for B. burgdorferi using Barbour-Stoenner-Kelly (BSK) medium is technically difficult, slow (requiring up to 6 to 12 weeks), has an extremely low diagnostic yield (<10% to 20%), and is not recommended for routine clinical use.
• Polarized Light Microscopy: Negative for monosodium urate or calcium pyrophosphate dihydrate crystals.

Two-Tiered Serologic Algorithm (STTT and MTTT)

Serologic evaluation is the gold standard diagnostic pillar for confirming Lyme disease. Testing must adhere to the validated two-tiered paradigm endorsed by the CDC, IDSA, and ACR:

• Standard Two-Tiered Testing (STTT):
  • First Tier: High-sensitivity enzyme immunoassay (EIA) or indirect immunofluorescence assay (IFA) utilizing whole-cell sonicate or recombinant antigens. If the first tier is negative, no further testing is indicated. If positive or equivocal, reflexive second-tier testing is performed.
  • Second Tier: Western blot immunoblotting. For patients presenting with joint effusion or symptoms present for greater than 30 days (which applies to virtually all patients with Lyme arthritis), only the IgG Western blot should be interpreted. An isolated positive IgM Western blot after 4 weeks of symptoms represents a false-positive result and must be disregarded.
  • CDC Criteria for IgG Positivity: Requires the presence of at least 5 out of 10 specific polypeptide bands: 18, 21 (OspC), 28, 30, 39, 41 (flagellin), 45, 58, 66, and 93 kDa. In late Lyme arthritis, IgG Western blot is positive in over 99% of untreated patients.
• Modified Two-Tiered Testing (MTTT):
  • Replaces the Western blot with a second, sequential enzyme immunoassay targeting distinct recombinant antigens (e.g., first-tier whole-cell lysate EIA followed by second-tier VlsE / C6 peptide EIA, or vice versa).
  • MTTT is FDA-cleared and endorsed by the 2020 IDSA/AAN/ACR guidelines. It demonstrates equivalent or superior sensitivity compared to STTT in early stages, maintains virtually 100% specificity in late Lyme arthritis, eliminates subjective immunoblot band interpretation, and improves inter-laboratory reproducibility.

Synovial Fluid Polymerase Chain Reaction (PCR)

Real-time polymerase chain reaction (RT-PCR) testing directly detects B. burgdorferi plasmid or chromosomal DNA (targeting OspA or flagellin genes) in synovial fluid or synovial biopsy tissue:

• Diagnostic Performance in Untreated Disease: Demonstrates high diagnostic sensitivity (75% to 90%) and exceptional specificity (>98%) in untreated Lyme arthritis.
• Role in Refractory Arthritis: Synovial fluid PCR rapidly becomes negative following effective antimicrobial therapy (typically within 2 to 4 weeks). A negative PCR in a patient with persistent joint swelling confirms bacterial eradication, indicating post-infectious immune-mediated synovitis and ruling out ongoing active spirochetal infection.
• Contraindication as a Screening Tool: PCR should not be used as an initial screening assay without concurrent serum serology, nor should it be utilized on urine, whole blood, or serum samples due to extremely low yield.

7. Classification and Clinical Differentiation

Clinical Stage Classification

Lyme disease progresses through three clinically distinct stages that dictate systemic and orthopaedic management:

• Stage 1 (Early Localized): Solitary erythema migrans lesion at tick bite site; constitutional symptoms (low-grade fever, myalgias, arthralgias); no objective joint effusion.
• Stage 2 (Early Disseminated): Multiple secondary annular cutaneous lesions; cranial neuropathy (Bell palsy), lymphocytic meningitis, or Bannwarth radiculoneuropathy; Lyme carditis (AV conduction block); migratory musculoskeletal pain without joint destruction.
• Stage 3 (Late Disseminated): Manifests months to years post-bite. Characterized by intermittent or persistent monoarthritis or asymmetric oligoarthritis (predominantly knee); marked synovial hypertrophy; rarely late chronic neuroborreliosis.

Validated Prediction Models: Baldwin Knee Criteria vs. Kocher Hip Criteria

In pediatric orthopaedics, the differentiation of an acute knee or hip effusion represents a critical clinical challenge. In non-endemic settings, the validated Kocher criteria (non-weight-bearing, oral temperature >38.5°C, ESR ≥40 mm/hr, peripheral WBC >12,000/mcL) reliably differentiate pyogenic septic arthritis from transient synovitis. However, in Lyme-endemic regions, applying the Kocher criteria to knee effusions leads to excessive unnecessary surgical arthrotomies because Lyme arthritis frequently produces elevated ESR and synovial leukocyte counts.

To address this clinical dilemma, Baldwin and colleagues (2016) developed and validated a multivariate clinical prediction model specifically for pediatric knee effusions in Lyme-endemic areas, identifying four independent multivariate predictors of pyogenic septic arthritis:

• Refusal to Bear Weight: Odds Ratio 5.3
• History of Fever (≥38.0°C / 100.4°F): Odds Ratio 3.3
• Erythrocyte Sedimentation Rate (ESR) ≥40 mm/hr: Odds Ratio 3.3
• Serum Peripheral Leukocyte Count (WBC) >12,000/mcL: Odds Ratio 2.3

When evaluated in endemic regions, the probability of pyogenic septic arthritis stratifies as follows: 0 predictors present = <2% probability of septic arthritis (>98% probability of Lyme arthritis); 1 predictor = 10%; 2 predictors = 35%; 3 predictors = 83%; and all 4 predictors present = 99% probability of septic arthritis. Furthermore, serum C-reactive protein (CRP) serves as an essential continuous discriminator: a CRP <4.0 mg/dL strongly favors Lyme arthritis, whereas a CRP ≥4.0 to 5.0 mg/dL strongly suggests acute bacterial septic arthritis.

8. Treatment

Medical Therapy: First-Line and Second-Line Antimicrobial Regimens

Lyme arthritis is primarily an infectious disease requiring definitive antimicrobial therapy to achieve spirochetal eradication:

• First-Line Oral Antimicrobial Regimens (Duration: 28 Days):
  • Doxycycline: 100 mg PO BID for adults. In pediatric patients, the dosage is 4.4 mg/kg/day divided twice daily (maximum 100 mg per dose). Per updated guidelines from the American Academy of Pediatrics (AAP) and IDSA, short courses of doxycycline (up to 28 days) are safe for children of all ages, as modern formulations do not cause the visible dental staining or enamel hypoplasia seen with older tetracyclines. Doxycycline is the preferred first-line agent due to excellent oral bioavailability, high synovial penetration, and concurrent coverage of Anaplasma phagocytophilum.
  • Amoxicillin: 500 mg PO TID for adults. In pediatric patients, the dosage is 50 mg/kg/day divided into 3 equal doses (maximum 500 mg per dose). Recommended as first-line therapy for pregnant or lactating women and as an alternative for young children.
  • Cefuroxime Axetil: 500 mg PO BID for adults. In pediatric patients, the dosage is 30 mg/kg/day divided twice daily (maximum 500 mg per dose). Serves as an effective second-line oral option for patients intolerant of penicillin and doxycycline.
• Second-Line Antimicrobial Protocol for Persistent or Recurrent Arthritis:
  • Resolution of joint effusion following antimicrobial therapy is gradual, frequently requiring 1 to 3 months. If significant joint swelling persists at the conclusion of the initial 28-day course, management is dictated by the degree of clinical improvement:
  • Partial Improvement / Mild Residual Effusion: A second consecutive 28-day course of an alternative oral antibiotic (e.g., amoxicillin if doxycycline was used initially) is recommended.
  • Minimal Response / Severe Persistent Effusion: Intravenous antimicrobial therapy is indicated: Ceftriaxone 2 g IV once daily for 14 to 28 days (pediatric dose: 50 to 75 mg/kg IV once daily, maximum 2 g/day). Intravenous alternatives for cephalosporin-allergic patients include Cefotaxime (2 g IV every 8 hours) or Penicillin G (18 to 24 million units IV daily administered continuously or divided every 4 hours).

Post-Infectious / Refractory Lyme Arthritis

Approximately 5% to 10% of patients fail to resolve joint inflammation despite receiving two full cycles of oral antibiotics or one cycle of oral plus one cycle of IV antibiotics. When persistent joint effusion persists for greater than 2 to 3 months following antibiotic completion and synovial fluid RT-PCR confirms absence of B. burgdorferi DNA, the diagnosis is antibiotic-refractory (post-infectious) Lyme arthritis. In this pathogen-cleared state, additional antibiotics provide no clinical benefit and expose patients to significant drug toxicity. Management shifts entirely to immunomodulatory therapies under rheumatologic co-management:

• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Full therapeutic anti-inflammatory doses (e.g., naproxen 500 mg BID, celecoxib 200 mg daily, or meloxicam 15 mg daily) provide baseline symptomatic relief.
• Intra-Articular Corticosteroid Infiltration: Infiltration of triamcinolone acetonide (40 mg) or triamcinolone hexacetonide (40 mg) into the affected joint provides rapid symptomatic improvement. Mandatory safety rule: Intra-articular corticosteroids must be withheld until the patient has completed full antimicrobial therapy and synovial fluid PCR has verified pathogen clearance, as premature injection during active infection impairs spirochetal eradication.
• Disease-Modifying Antirheumatic Drugs (DMARDs): Oral methotrexate (15 to 25 mg once weekly with folic acid supplementation) or hydroxychloroquine (200 to 400 mg daily) is initiated for persistent, proliferative synovitis failing NSAIDs and corticosteroid injection.
• Biologic Agents (TNF-Alpha Inhibitors): For severe, erosive, or DMARD-refractory disease, TNF-alpha inhibitors (e.g., etanercept 50 mg weekly or adalimumab 40 mg biweekly) successfully induce remission by suppressing synovial cytokine hyperactivation.

Operative Treatment: Arthroscopic Subtotal Synovectomy

When proliferative, villous synovitis remains refractory to both antimicrobial eradication and comprehensive immunomodulatory medical therapy, surgical intervention is indicated:

• Goals of Surgery: Complete mechanical debridement of hypertrophic, hypervascular, inflammatory synovium to eliminate local production of chondrolytic matrix metalloproteinases and pro-inflammatory cytokines, eradicate recurrent joint effusions, alleviate pain, and halt progressive cartilage loss. Arthroscopic synovectomy is distinctly preferred over open synovectomy due to lower morbidity, superior visualization of posterior compartments, accelerated rehabilitation, and reduced risk of postoperative arthrofibrosis.
• Surgical Technique and Systematic Compartmental Debridement:
  • Portal Placement: Standard anteromedial (AM) and anterolateral (AL) portals are established for diagnostic arthroscopy. Superomedial (SM) and superolateral (SL) portals are established 2.5 cm proximal to the superior patellar pole for dedicated suprapatellar pouch triangulation.
  • Debridement Sequence: Synovectomy begins in the suprapatellar pouch using high-flow suction motorized shavers (4.0 to 5.5 mm aggressive full-radius resector) supplemented by radiofrequency ablation for hemostasis. The resection systematically progresses through the medial and lateral gutters, the anterior interval, the infrapatellar fat pad recess, and the intercondylar notch.
  • Posterior Compartment Clearance: Neglecting the posterior compartments is the primary technical cause of surgical failure and persistent effusion. Access to the posteromedial and posterolateral compartments is established via trans-notch visualization or dedicated posteromedial (PM) and posterolateral (PL) portals with the knee flexed to 90 degrees. Complete subtotal synovectomy is performed under continuous visual control, strictly maintaining the shaver aperture directed toward the joint space away from the posterior capsule to protect the popliteal neurovascular bundle.

Indications & Contraindications

Precise surgical criteria prevent premature or inappropriate operative intervention:

• Indications for Arthroscopic Synovectomy:
  • Persistent, symptomatic, proliferative synovitis with marked joint effusion persisting for >6 to 12 months.
  • Objective failure of at least two guideline-directed cycles of antimicrobial therapy (e.g., 28 days of oral antibiotics followed by 14 to 28 days of IV ceftriaxone).
  • Negative synovial fluid B. burgdorferi PCR confirming spirochetal clearance.
  • Failure or intolerance of a 3- to 6-month trial of post-infectious immunomodulatory therapy (NSAIDs, intra-articular corticosteroids, or DMARDs).
• Contraindications to Synovectomy:
  • Active Spirochetal Infection: Presence of positive synovial fluid B. burgdorferi PCR mandates re-treatment with systemic antibiotics rather than surgical resection.
  • Incomplete Medical Antibiotic Courses: Surgery is contraindicated before completing appropriate antibiotic therapy.
  • End-Stage Tri-Compartmental Osteoarthritis (Ahlbäck Grade ≥3 / Kellgren-Lawrence Grade 4): Severe structural joint collapse, extensive bone-on-bone contact, and severe angular deformity will not benefit from isolated synovectomy; total knee arthroplasty (TKA) is indicated.
  • Active Uncontrolled Systemic Infection or Active Cutaneous Infection Over Portals.

9. Outcome and Prognosis

Antimicrobial Eradication Rates and PROMs

The overall prognosis for patients with Lyme arthritis is excellent when recognized and treated with guideline-directed antimicrobial protocols:

• Primary Antimicrobial Cure Rate: Complete and permanent resolution of joint inflammation is achieved in over 85% to 90% of patients following one or two standard courses of oral or intravenous antimicrobial therapy. The resolution of synovial effusion is typically gradual, with median resolution times ranging from 4 to 12 weeks after antibiotic completion.
• Long-Term Joint Function and PROMs: Long-term prospective cohort evaluations demonstrate that patients treated successfully for Lyme arthritis regain normal joint motion, full muscular strength, and return to unrestricted physical activity. Validated patient-reported outcome measures, including the Knee Injury and Osteoarthritis Outcome Score (KOOS), International Knee Documentation Committee (IKDC) subjective score, and Pediatric Quality of Life Inventory (PedsQL), demonstrate score normalization comparable to healthy age-matched control populations within 6 to 12 months following pathogen clearance.

Surgical Outcomes Following Arthroscopic Synovectomy

In the 5% to 10% cohort of patients with chronic antibiotic-refractory proliferative synovitis, arthroscopic subtotal synovectomy provides reliable and durable clinical relief. Seminal and contemporary surgical series document successful joint resolution in 75% to 85% of operative cases at long-term follow-up (Schoen et al. 1991). Following complete compartmental synovectomy, patients demonstrate prompt elimination of recurrent effusions, pain relief, and prevention of progressive secondary cartilage degradation.

Prognostic Biomarkers and Genetic Predictors of Refractory Disease

Several biologic and clinical markers predict a prolonged, refractory clinical course:

• HLA-DRB1 Allelic Susceptibility: Patients carrying HLA-DRB1*0401, *0101, *0404, or *0405 alleles have a substantially higher relative risk of developing antibiotic-refractory proliferative synovitis due to enhanced presentation of self-mimicking peptides to autoreactive T cells.
• Synovial Fluid Chemokine Profiles: Markedly elevated pre-treatment synovial fluid levels of the Th1-recruiting chemokines CXCL9 and CXCL10 correlate strongly with prolonged arthritis duration and failure of primary oral antimicrobial therapy.
• Delayed Diagnosis: Symptom duration exceeding 6 to 12 months prior to the initiation of definitive antibiotic therapy correlates with higher rates of persistent synovial hypertrophy, secondary chondral thinning, and prolonged recovery trajectories.

10. Complications

Complications associated with Lyme arthritis span immediate adverse pharmacologic reactions, late secondary articular degeneration, and surgical morbidity:

11. Pearls and Pitfalls

Mastery of Lyme arthritis management requires avoiding classic diagnostic traps and applying key clinical pearls:

• The “Walk-In Effusion” Paradox: In a patient presenting from an endemic region during late spring, summer, or autumn with a massive, tense, bulging knee effusion who nonetheless walks into clinic with only a mild antalgic limp and preserved range of motion, presume Lyme arthritis until proven otherwise. Pyogenic septic arthritis produces agonizing guarding and complete refusal of passive motion.
• The Western Blot 30-Day Rule: Never interpret an IgM Western blot for patients who have experienced musculoskeletal symptoms for greater than 4 weeks. In late-stage disease, an isolated positive IgM Western blot with a negative IgG Western blot represents a false positive. Only a positive IgG Western blot (≥5 of 10 diagnostic bands) or a validated modified two-tiered testing (MTTT) algorithm confirms late Lyme disease.
• The CRP Cleavage Benchmark: In pediatric patients presenting with acute knee effusions where synovial fluid leukocyte counts fall into the ambiguous 30,000 to 75,000 cells/mcL range, serum C-reactive protein (CRP) is the single most valuable discriminating laboratory parameter. A serum CRP <4.0 mg/dL strongly favors Lyme arthritis, whereas a CRP ≥4.0 to 5.0 mg/dL strongly warrants consideration of acute bacterial septic arthritis.
• Avoid Premature Corticosteroid Infiltration: Never inject intra-articular corticosteroids into an acute joint effusion before serologic confirmation and antimicrobial therapy have been completed. Infiltrating steroids into a joint harboring live B. burgdorferi impairs host immune clearance, promotes spirochetal persistence, and significantly increases the failure rate of subsequent antibiotic regimens.
• Resist the Urge for Emergent Arthrotomy: In an afebrile, clinically non-toxic patient with a massive knee effusion and a synovial leukocyte count of 50,000 cells/mcL, avoid rushing immediately to the operating room for emergent surgical incision and drainage. Obtain a rapid Lyme C6 ELISA or multiplex PCR, check serum inflammatory markers, and apply the Baldwin criteria. Unnecessary arthrotomy introduces operative morbidity, increases hospital costs, and fails to treat the underlying systemic spirochetal infection.
• Complete Posterior Compartment Synovectomy: When performing arthroscopic synovectomy for refractory proliferative synovitis, the surgeon must systematically clear the posteromedial and posterolateral compartments via trans-notch visualization or dedicated posterior portals. Leaving residual hypertrophic synovium within the posterior capsular recesses is the leading technical cause of recurrent postoperative effusions.
• Strictly Limit Antibiotics to Two Courses: Do not administer prolonged, continuous, or repeated courses of antimicrobial therapy beyond 8 weeks. Multiple randomized controlled trials have conclusively demonstrated that extended antibiotic therapy beyond 2 months does not improve long-term outcomes in post-infectious Lyme arthritis or PTLDS, while drastically increasing the risk of life-threatening line sepsis, Clostridioides difficile colitis, and antimicrobial resistance.

12. Controversy

Diagnostic Ambiguity in Endemic Zones: Culture-Negative Septic Arthritis vs. Lyme Arthritis

In pediatric patients presenting with acute knee effusions, waiting 48 to 72 hours for send-out Western blot results creates intense clinical tension. When synovial leukocyte counts exceed 50,000 cells/mcL and inflammatory markers are borderline, clinicians face the difficult choice between performing an emergent joint washout (risking unnecessary operative morbidity in a child with Lyme arthritis) versus initiating observation (risking irreversible chondral necrosis from an unrecognized pyogenic infection). The adoption of rapid modified two-tiered testing (MTTT), in-house C6 peptide ELISAs, and multiplex synovial fluid PCR assays with 4- to 6-hour turnaround times has significantly alleviated this diagnostic dilemma. However, institutional protocols vary regarding whether an equivocal case should undergo immediate arthroscopic irrigation or a 24-hour observation period on intravenous antibiotics while pending definitive serology.

Post-Antibiotic Proliferative Synovitis: Biological DMARD Escalation vs. Arthroscopic Synovectomy

Significant clinical debate surrounds the optimal management strategy for patients with antibiotic-refractory proliferative Lyme arthritis following two failed antibiotic cycles and confirmed negative PCR. Medical rheumatologists advocate for systemic immunosuppression utilizing oral methotrexate or biologic TNF-alpha inhibitors (e.g., etanercept, adalimumab) to quiet the autoimmune cascade without surgical intervention. Conversely, orthopaedic surgeons emphasize that extensive, organized villonodular pannus produces mechanical joint dysfunction and continuous enzymatic cartilage erosion that responds slowly or incompletely to medical DMARDs alone. Proponents of early arthroscopic subtotal synovectomy demonstrate that definitive mechanical resection of the diseased synovial lining promptly clears the source of destructive cytokines, provides durable disease resolution in >80% of patients, and eliminates the need for prolonged systemic immunosuppression with its attendant infectious risks.

Extended Antimicrobial Therapy for Persistent Symptoms

A contentious debate persists between conventional evidence-based medical organizations (IDSA, AAP, ACR, CDC) and alternative advocacy groups regarding the concept of “chronic Lyme disease” and the use of long-term (months to years) intravenous or oral antimicrobial regimens. Extensive randomized, double-blind, placebo-controlled trials have evaluated prolonged antibiotic therapy for persistent post-treatment symptoms, conclusively demonstrating no sustained benefit in cognitive performance, functional scores, or physical outcomes compared to placebo. Furthermore, extended antimicrobial therapy has resulted in severe adverse events, including catheter-associated bloodstream infections, septic thrombophlebitis, endocarditis, and death. Clinical consensus firmly dictates that antimicrobial therapy should never exceed 2 months total duration.

13. Evidence-Based Synthesis

Modern clinical decision-making is grounded in high-quality randomized controlled trials and prospective registry analyses, corroborated by seminal biomechanical and anatomical descriptions.

14. References

• Lantos PM, Rumbaugh J, Bockenstedt LK et al. Clinical Practice Guidelines by the Infectious Diseases Society of America, American Academy of Neurology, and American College of Rheumatology: 2020 Guidelines for the Prevention, Diagnosis, and Treatment of Lyme Disease. Neurology. 2021. doi:10.1212/WNL.0000000000011151 [Level I: Clinical Practice Guideline]
• Baldwin KD, Brusalis CM, Nduaguba AM et al. Predictive Factors for Differentiating Between Septic Arthritis and Lyme Disease of the Knee in Children. J Bone Joint Surg Am. 2016. doi:10.2106/JBJS.14.01331 [Level III: Retrospective Comparative Study]
• Cruz AI Jr, Anari JB, Ramirez JM et al. Distinguishing Pediatric Lyme Arthritis of the Hip from Transient Synovitis and Acute Bacterial Septic Arthritis: A Systematic Review and Meta-analysis. Cureus. 2018. doi:10.7759/cureus.2112 [Level I: Systematic Review / Meta-analysis]
• Schoen RT, Aversa JM, Rahn DW et al. Treatment of refractory chronic Lyme arthritis with arthroscopic synovectomy. Arthritis Rheum. 1991. doi:10.1002/art.1780340817 [Level IV: Therapeutic Case Series]
• Wormser GP, Dattwyler RJ, Shapiro ED et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006. doi:10.1086/508667 [Level I: Clinical Practice Guideline]

15. Master Class Pro-Tip

When evaluating an acute or subacute knee effusion in a patient from an endemic region, the clinical hallmark distinguishing Lyme arthritis from acute bacterial septic arthritis is the striking discordance between physical volume and patient distress. Lyme arthritis presents as a ‘cold’ or mildly warm, massive effusion with preserved passive range of motion and often the ability to bear weight, in stark contrast to the agonizing irritability and complete refusal of motion typical of pyogenic sepsis. Before subjecting an equivocal case to emergent surgical arthrotomy, obtain a rapid C6 ELISA, check serum CRP, and perform arthrocentesis for cell count and Borrelia burgdorferi PCR. In confirmed antibiotic-refractory proliferative synovitis, arthroscopic synovectomy must be comprehensive: enter the posteromedial and posterolateral compartments through dedicated high-flow portals, as residual posterior synovium is the primary driver of recalcitrant joint effusion.

Master Class Surgical Pearl: Lyme Arthritis Management